The IPO Buzz: Scribe Therapeutics Upsizes IPO & Prices it at $15 – Top of Range
Scribe Therapeutics (SCTX) upsized its IPO at pricing to 8.58 million shares – up from 7.15 million in the prospectus – and priced the deal at $15.00 – the top of its range – to raise $128.7 million on Thursday night, July 23, 2026. The Phase 1 cardiovascular-focused biotech had marketed its IPO at a […]
July 23, 2026 Read More